Korea S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
106,600
KRW
+1.81%
+3.80%
+37.90%
2023
Sam Chun Dang Pharm. Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
2021
Sam Chun Dang Pharm. Co., Ltd announced that it has received KRW 30 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, and other investor
CI
Sam Chun Dang Pharm. Co., Ltd announced that it has received KRW 20 billion in funding from Korea Investment Partners Co. Ltd.
On November 19, 2018, Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:A000250) closed the transaction.
Sam Chun Dang Pharm. Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Sam Chun Dang Pharm. Co., Ltd announced that it has received KRW 30 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, and other investor
21-02-25
CI
Sam Chun Dang Pharm. Co., Ltd announced that it expects to receive KRW 30 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, and another investors
21-02-23
CI
Sam Chun Dang Pharm. Co., Ltd announced that it has received KRW 20 billion in funding from Korea Investment Partners Co. Ltd.
18-11-18
CI
Sam Chun Dang Pharm. Co., Ltd announced that it expects to receive KRW 20 billion in funding from Korea Investment Partners Co. Ltd.
18-11-14
CI
Breckenridge Pharmaceutical, Inc. Enters into Multi-Product Agreement with Sam Chun Dang Pharm. Co., Ltd
17-07-03
CI
Sam Chun Dang Pharm. Co.,Ltd completed the acquisition of 61.27% stake in DHP Korea Ltd.
12-12-26
CI
Sam Chun Dang Pharm. Co.,Ltd agreed to acquire 61.27% stake in DHP Korea Ltd. for approximately KRW 14 billion.
12-12-25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Companyâs products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
More about the company
1st Jan change
Capi.
+37.90% 1.76B +19.62% 43.34B +20.44% 21.96B +10.86% 14.09B +13.07% 13.64B +37.46% 11.43B -8.59% 6.86B -0.05% 6.79B -8.87% 5.73B +8.46% 5.22B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SAM CHUN DANG PHARM. CO., LTD 
